Tofacitinib Prevents Radiographic Progression in Rheumatoid Arthritis.
10.3346/jkms.2013.28.8.1134
- Author:
Joon Wan KIM
1
;
In Ah CHOI
;
Eun Young LEE
;
Yeong Wook SONG
;
Eun Bong LEE
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. leb7616@snu.ac.kr
- Publication Type:Original Article ; Clinical Trial, Phase II ; Research Support, Non-U.S. Gov't
- Keywords:
Arthritis, Rheumatoid;
Radiographic Progression;
Tofacitinib
- MeSH:
Adult;
Aged;
Antirheumatic Agents/therapeutic use;
Arthritis, Rheumatoid/*drug therapy/prevention & control/radiography;
Cohort Studies;
Disease Progression;
Female;
Humans;
Male;
Middle Aged;
Piperidines/*therapeutic use;
Protein Kinase Inhibitors/*therapeutic use;
Pyrimidines/*therapeutic use;
Pyrroles/*therapeutic use;
Severity of Illness Index;
Treatment Outcome
- From:Journal of Korean Medical Science
2013;28(8):1134-1138
- CountryRepublic of Korea
- Language:English
-
Abstract:
Tofacitinib, a novel Janus kinase inhibitor, may prevent structural damage in rheumatoid arthritis (RA). In this cohort study, we compared radiographic progression of hand joints between 21 RA patients who took tofacitinb for 18 months in a phase IIb and its extension study and 42 patients who took conventional disease modifying antirheumatic drugs (DMARDs), using simple erosion narrowing score. For tofacitinib group, changes before and after the treatment were also compared. The changes of erosion and sum scores were significantly less in tofacitinib than DMARDs group (for erosion, -0.60 +/- 1.83 vs 0.51 +/- 1.77, P = 0.038; for sum, -0.50 +/- 1.72 vs 1.57 +/- 4.13, P = 0.012). Joint space narrowing score (JSN) was also less in tofacitinib group (0.095 +/- 0.58 vs 1.06 +/- 2.60, P = 0.055). In tofacitinib group, yearly rates of both erosion and JSN were significantly decreased after administration of tofacitinib (For erosion, 0.62 +/- 0.93 to -0.14 +/- 0.48, P = 0.009; for JSN, 0.47 +/- 0.64 to 0.03 +/- 0.40, P = 0.032), as was change of sum score (1.09 +/- 1.27 to -0.10 +/- 0.63, P < 0.001). In conclusion, tofacitinib may prevent structural damage caused by RA.
